Clinical experience with paliperidone palmitate in a specialty hospital in the Philippines: A short report
- Author:
Amadeo A. Alinea, Jr.
1
;
Carl Abelardo T. Antonio
;
Amiel Nazer C. Bermudez
;
Kim L. Cochon
;
Maria Fatima V. Martinez
;
Jonathan P. Guevarra
Author Information
- Publication Type:Journal Article
- MeSH: Paliperidone Palmitate; Schizophrenia
- From: The Philippine Journal of Psychiatry 2023;4(1-2):47-
- CountryPhilippines
- Language:English
-
Abstract:
Objectives:This study aimed to describe the clinical outcomes related to theintroduction of Paliperidone Palmitate in a specialty hospital in the Philippines.
Methodology:Cross-sectional study among patients with Schizophrenia seen at thepsychiatry service of a specialty hospital catering to war veterans who were initiated onPaliperidone Palmitate. We reviewed and abstracted baseline patient data from themedical record of eligible patients. Outcome of treatment was collected through a one-time objective assessment of the patient by a third-party psychiatrist using theStructured Clinical Interview for Symptoms of Remission (SCI-SR) tool.
Results:A total of 30 patients were recruited for the study from August 2020 and June2021, the majority of whom were males (80%), residents of the National Capital Region(50%) and single (20%). The median duration from schizophrenia diagnosis to initiation of Paliperidone treatment was 19.50 years (IQR: 16.60 – 33.50). In eight patients (22.67%),other antipsychotic drugs were discontinued following initiation of Paliperidonetreatment; in the remaining 22 participants (73.33%), Paliperidone was taken concurrentlywith other antipsychotic drugs. The median duration from the initiation of Paliperidonetreatment to follow-up assessment was 27.20 months (IQR: 24.73 – 30.50), with allparticipants having at least 6 months of treatment. At follow-up assessment, allparticipants were classified to be in remission.
Conclusion:In this study among patients with schizophrenia seen in a specialtyhospital in the Philippines, we found evidence that clinical outcomes with PaliperidonePalmitate were comparable to those given a combination of oral and long- actingantipsychotics.
